FDA Puts Breast Milk Nutrient Testers into Official Safety Category
Published Date: 5/9/2025
Rule
Summary
The FDA is officially putting breast milk macronutrient test systems into a special safety group called Class II. This means these devices will have clear rules to keep them safe and effective, helping moms and babies get better access to these helpful tools faster. This change cuts red tape without adding extra costs, making it easier for companies to bring these devices to market.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Breast Milk Tests Reclassified to Class II
The FDA has classified breast milk macronutrient test systems as Class II (special controls). This means the FDA says these devices will have clear safety and effectiveness rules and that patients — including breastfeeding moms and babies — should get better and faster access because regulatory burdens are reduced.
Reduced Rules for Device Makers
The FDA says reclassifying these test systems to Class II (special controls) reduces regulatory burdens and makes it easier for companies to bring breast milk macronutrient test systems to market. The agency states this change cuts red tape without adding extra costs for manufacturers.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2025-04978, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA is delaying a new rule about nonprescription drugs that have extra conditions for use. Originally set to start on March 21, 2025, the rule’s start date is now pushed back to May 27, 2025, to allow more time for review. This affects drug makers and consumers by giving everyone extra time to prepare for the new requirements without any immediate cost changes.
2025-01840, Nonprescription Drug Product With an Additional Condition for Nonprescription Use
The FDA’s new rule about nonprescription drugs needing extra conditions before use was set to start on January 27, 2025, but it’s now delayed until March 21, 2025. This delay follows a presidential order to pause and review new rules before they take effect. Drug makers, sellers, and consumers should note the new start date and get ready for the updated rules soon.
2026-20063, Request for Nominations for Voting Members of Food and Drug Administration Advisory Committees
The FDA is looking for smart, qualified people to join its advisory committees and help make important decisions about food and drugs. If you have the right skills, you can apply anytime, but get your nomination in by November 30, 2026, for the best chance at current openings. This is a great chance to influence public health without any cost to you!
Previous / Next Documents
Previous: 2025-08146, Medical Devices; Immunology and Microbiology Devices; Classification of the Cytomegalovirus Nucleic Acid Detection Device for Congenital Cytomegalovirus Infection
The FDA is officially putting a new test for detecting congenital cytomegalovirus (CMV) into a special safety category called Class II. This means the test will have clear rules to make sure it’s safe and works well, helping doctors and patients get access to this important tool faster. This change affects device makers and healthcare providers and aims to speed up innovation without extra costs or delays.
Next: 2025-08148, Medical Devices; Clinical Chemistry and Clinical Toxicology Devices; Classification of the Voriconazole Test System
The FDA is officially putting the voriconazole test system into a special safety category called Class II, which means it has extra rules to keep it safe and effective. This change helps patients get access to this important medical test faster and with fewer red tapes. If you make or use these tests, get ready for new rules that kick in soon but won’t break the bank.